# MiRXES Pte

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mirxes-pte

- Industry: Biotechnology
- Headquarters: Singapore, Singapore
- Website: www.mirxes.com
- Total disclosed funding: $257M
- Latest round: Series D (Jul 25, 2023)
- Investors on record: 15

## About

Based in Singapore, and established in 2014, MiRXES Pte Ltd is a biotechnology company that provides the early diagnostic detection of cancer and other diseases. It spun off from Agency of Science, Technology and Research. It has additaionals offices in China, Hong Kong, Japan, and USA. In 2015, it launched ID3EAL suite of miRNA discovery tools. In 2016, it established production bases of in vitro diagnostic in Singapore. In 2018, it established joint R&D labs with Beth Israel, Deaconess Medical Center, Boston, USA, and the National University of Singapore. In 2020, it provides COVIND-19 PCR test kit and sold to 45 countries. In July 2023, MiRXES Pte Ltd raised USD 50 million in series D funding from new investors Mitsui & Co., Ltd., China Fellow Partners, Agency for Science, Technology and Research, and returning investor EDBI, and NHH Ventures. 

The company provides GASTROClear for the early detection of gastric cancer, microRNA-based blood test. It has technology platforms, including ID3EAL Suite, and ID3EAL panoramiR miRNA knowledge panel.  It also provides solutions, which can be divided into genomics, cancer screening, cancer treatment selection, and infectious diseases. The genomics solutions include clinical sequencing, and research sequencing. The infectious diseases detection tools include fortitude 2.1, fortitude syndromic panel, swab & saliva collection, and RNA extraction kits & instruments.

The company plans to series D funding for expansion in the market of stomach cancer blood test GASTROClear in China, Japan, and Southeast Asia. It also plans to list on Hong Kong Stock Exchange.

## Funding rounds

- Series D, Jul 25, 2023, $50M — SG Growth Capital, Mitsui & Co., China Fellow Partners, Agency for Science, Technology and Research, NHH Ventures, Nova Venture Partners, LLC.
- Series C, Feb 22, 2022, $87M — SG Growth Capital, Keytone Ventures, CDG Invest Growth, CR Capital, Rock Springs Capital, CCB International, New Horizons Venture Capital
- Series C, Jul 8, 2021, $77M — SG Growth Capital, Keytone Ventures, CCB International Asset Management, CR Capital, Rock Springs Capital
- Series A, Aug 1, 2019, $40M — Gaorong Ventures, VentureCraft
- Seed, Dec 1, 2016, $2.8M — VentureCraft

## Investors

- VentureCraft (https://capitalatlas.ai/funds/venturecraft) — Seed, Series A
- Gaorong Ventures (https://capitalatlas.ai/funds/gaorong-ventures) — Series A
- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series C, Series D
- Keytone Ventures (https://capitalatlas.ai/funds/keytone-ventures) — Series C
- CCB International Asset Management (https://capitalatlas.ai/funds/ccb-international-asset-management) — Series C
- CR Capital (https://capitalatlas.ai/funds/cr-capital) — Series C
- Rock Springs Capital — Series C
- CDG Invest Growth (https://capitalatlas.ai/funds/cdg-invest-growth) — Series C
- CCB International (https://capitalatlas.ai/funds/ccb-international) — Series C
- New Horizons Venture Capital (https://capitalatlas.ai/funds/new-horizons-venture-capital) — Series C
- Mitsui & Co. — Series D
- China Fellow Partners (https://capitalatlas.ai/funds/china-fellow-partners) — Series D
- Agency for Science, Technology and Research — Series D
- NHH Ventures — Series D
- Nova Venture Partners, LLC. — Series D